BISPECIFIC ANTIBODIES MARKET ANALYSIS
The global bispecific antibodies market is expected to witness significant growth, owing to increasing research and development of novel bispecific antibodies. For instance, in January 2019, the Chinese Academy of Medical Sciences & Peking Union Medical College developed a new bispecific aptamer that enhances immune cytotoxicity against MUC1-positive tumor cells.
Moreover, in September 2018, researchers from China Pharmaceutical University constructed and expressed a fully human, bispecific, single-chain diabody that can bind to vascular endothelial growth factor 165 (VEGF165) and programmed death-1 in Pichia pastoris.
In August 2018, UCB Pharma, a scientific research company based in Belgium, conducted research on the molecular factors in bispecific antibody multimerisation and revealed that the monomer level of single-chain variable fragment-containing bispecific antibody formats can be increased by conversion of the single-chain variable fragment to a disulfide-stabilized single-chain variable fragment.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
